Skip to main content
Erschienen in: European Child & Adolescent Psychiatry 4/2008

01.06.2008 | ORIGINAL CONTRIBUTION

Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder

A growth mixture modelling analysis

verfasst von: Edmund J. S. Sonuga-Barke, Pol Van Lier, James M. Swanson, David Coghill, Sharon Wigal, Mieke Vandenberghe, Simon Hatch

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To use growth mixture modelling (GMM) to identify subgroups of children with attention deficit hyperactive disorder (ADHD) who have different pharmacodynamic profiles in response to extended release methylphenidate as assessed in a laboratory classroom setting.

Methods

GMM analysis was performed on data from the COMACS study (Comparison of Methylphenidates in the Analog Classroom Setting): a large (n = 184) placebo-controlled cross-over study comparing three treatment conditions in the Laboratory School Protocol (with a 1.5-h cycle of attention and deportment assessments). Two orally administered, once-daily methylphenidate (MPH) bioequivalent formulations [Metadate CD/Equasym XL (MCD-EQXL) and Concerta XL (CON)] were compared with placebo (PLA).

Results

Three classes of children with distinct severity profiles in the PLA condition were identified. For both MCD-EQXL and CON, the more severe their PLA symptoms the better, the children’s response. However, the formulations produced different growth curves by class, with CON having essentially a flat profile for all three classes (i.e. no effect of PLA severity) and MCD-EQXL showing a marked decline in symptoms immediately post-dosing in the two most severe classes compared with the least severe. Comparison of daily doses matched for immediate-release (IR) components accounted for this difference.

Conclusion

The results suggest considerable heterogeneity in the pharmacodynamics of MPH response by children with ADHD. When treatment response for near-equal, bioequivalent daily doses the two formulations was compared, marked differences were seen for children in the most severe classes with a strong curvilinear trajectory for MCD-EQXL related to the greater IR component.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Adesman A (2004) Flawed attention-deficit/hyperactivity disorder mediation comparison. Pediatrics 114:1132PubMedCrossRef Adesman A (2004) Flawed attention-deficit/hyperactivity disorder mediation comparison. Pediatrics 114:1132PubMedCrossRef
2.
Zurück zum Zitat Antrop I, Buysse A, Roeyers H, Van Oost P (2005) Activity in children with ADHD during waiting situations in the classroom: a pilot study. Br J Educ Psychol 75:51–69PubMedCrossRef Antrop I, Buysse A, Roeyers H, Van Oost P (2005) Activity in children with ADHD during waiting situations in the classroom: a pilot study. Br J Educ Psychol 75:51–69PubMedCrossRef
3.
Zurück zum Zitat Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJS, Taylor E (2006) Long-acting medications for the hyperkinetic disorders – a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495PubMedCrossRef Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJS, Taylor E (2006) Long-acting medications for the hyperkinetic disorders – a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495PubMedCrossRef
4.
5.
Zurück zum Zitat Bollen K, Long JS (1993) Testing structural equation models. Sage, Newbury Park Bollen K, Long JS (1993) Testing structural equation models. Sage, Newbury Park
6.
Zurück zum Zitat Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale
7.
Zurück zum Zitat Cuijpers P van Lier PAC, van Straten A, Donker M (2005) Examining differential effects of psychological treatment of depressive disorder: an application of trajectory analyses. J Affect Disord 89:137–146CrossRef Cuijpers P van Lier PAC, van Straten A, Donker M (2005) Examining differential effects of psychological treatment of depressive disorder: an application of trajectory analyses. J Affect Disord 89:137–146CrossRef
8.
Zurück zum Zitat Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJH, Hatch SJ (2002) Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40:175–184PubMed Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJH, Hatch SJ (2002) Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40:175–184PubMed
9.
Zurück zum Zitat Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Bitiello B, Wells K (1996) Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 35:1304–1313PubMedCrossRef Greenhill LL, Abikoff HB, Arnold LE, Cantwell DP, Conners CK, Elliott G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March JS, Newcorn J, Pelham WE, Severe JB, Swanson JM, Bitiello B, Wells K (1996) Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 35:1304–1313PubMedCrossRef
10.
Zurück zum Zitat Hazell P, Lewin T, Sly K (2005) What is a clinically important level of improvement in symptoms of attention-deficit/hyperactivity disorder? Aust NZ J Psychiatry 39:354–358CrossRef Hazell P, Lewin T, Sly K (2005) What is a clinically important level of improvement in symptoms of attention-deficit/hyperactivity disorder? Aust NZ J Psychiatry 39:354–358CrossRef
11.
Zurück zum Zitat Kass RE, Raftery AE (1995) Bayes factors. J Am Stat Assoc 90:773–795CrossRef Kass RE, Raftery AE (1995) Bayes factors. J Am Stat Assoc 90:773–795CrossRef
12.
Zurück zum Zitat Muthén BO, Shedden K (1999) Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55:463–469PubMedCrossRef Muthén BO, Shedden K (1999) Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55:463–469PubMedCrossRef
13.
Zurück zum Zitat Muthén LK, Muthén BO (1998–2006) Mplus user’s guide, 4th edn. Muthén & Muthén Los Angeles Muthén LK, Muthén BO (1998–2006) Mplus user’s guide, 4th edn. Muthén & Muthén Los Angeles
14.
Zurück zum Zitat Satorra A (2000) Scaled and adjusted restricted tests in multi-sample analysis of moment structures. In: Heijmans RDH, Pollock DSG, Satorra A (eds) Innovations in multivariate statistical analysis. A Festschrift for Heinz Neudecker. Kluwer Academic Publishers, London, pp 233–247 Satorra A (2000) Scaled and adjusted restricted tests in multi-sample analysis of moment structures. In: Heijmans RDH, Pollock DSG, Satorra A (eds) Innovations in multivariate statistical analysis. A Festschrift for Heinz Neudecker. Kluwer Academic Publishers, London, pp 233–247
15.
Zurück zum Zitat Sonuga-Barke EJS, Swanson JM, Coghill D, DeCory HH, Hatch SJ (2004) Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28PubMedCrossRef Sonuga-Barke EJS, Swanson JM, Coghill D, DeCory HH, Hatch SJ (2004) Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28PubMedCrossRef
16.
Zurück zum Zitat Sonuga-Barke EJS, Swanson J, Markowitz J, Coghill D, Vandenberghe M, Hatch S (2007) Sex differences in the pharmacodynamics of ADHD children’s response to methylphenidate: a comparison of two formulations. J Am Acad Child Adolesc Psychiatry 46:701–710PubMedCrossRef Sonuga-Barke EJS, Swanson J, Markowitz J, Coghill D, Vandenberghe M, Hatch S (2007) Sex differences in the pharmacodynamics of ADHD children’s response to methylphenidate: a comparison of two formulations. J Am Acad Child Adolesc Psychiatry 46:701–710PubMedCrossRef
17.
Zurück zum Zitat Swanson JM (1992) School based assessments and interventions for ADD students. KC Publishing, Irvine Swanson JM (1992) School based assessments and interventions for ADD students. KC Publishing, Irvine
18.
Zurück zum Zitat Swanson JM, Agler D, Fineberg E, Wigal S, Flynn D, Fineberg K, Quintana Y, Talebi H (1999) University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies. In: Greenhill L, Osman B (eds) Ritalin: theory and practice, 2nd edn. Mary Ann Liebert, Inc. Publishers, New York, pp 405–430 Swanson JM, Agler D, Fineberg E, Wigal S, Flynn D, Fineberg K, Quintana Y, Talebi H (1999) University of California, Irvine, laboratory school protocol for pharmacokinetic and pharmacodynamic studies. In: Greenhill L, Osman B (eds) Ritalin: theory and practice, 2nd edn. Mary Ann Liebert, Inc. Publishers, New York, pp 405–430
19.
Zurück zum Zitat Swanson JM, the COMACS Group (2004) Flawed attention-deficit/hyperactivity disorder mediation comparison: in reply. Pediatrics 114:1132–1133CrossRef Swanson JM, the COMACS Group (2004) Flawed attention-deficit/hyperactivity disorder mediation comparison: in reply. Pediatrics 114:1132–1133CrossRef
20.
Zurück zum Zitat Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S (2003) Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204–211PubMedCrossRef Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S (2003) Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204–211PubMedCrossRef
21.
Zurück zum Zitat Swanson J, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, Freid J, Wigal S (2002) The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6:S73–S88PubMed Swanson J, Lerner M, Wigal T, Steinhoff K, Greenhill L, Posner K, Freid J, Wigal S (2002) The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 6:S73–S88PubMed
22.
Zurück zum Zitat Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Dirksen SJH, Hatch SJ, COMACS Study Group (2004) A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS study). Pediatrics 113:E206–E216 Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Dirksen SJH, Hatch SJ, COMACS Study Group (2004) A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS study). Pediatrics 113:E206–E216
23.
Zurück zum Zitat Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder – first upgrade European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13:17–130CrossRef Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder – first upgrade European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13:17–130CrossRef
24.
Zurück zum Zitat van Lier PAC, van der Ende J, Koot HM, Verhulst FC (2007) Which better predicts conduct problems? The relationship of trajectories of conduct problems with ODD and ADHD symptoms form childhood to adolescence. J Child Psychol Psychiatry 48:601–608PubMedCrossRef van Lier PAC, van der Ende J, Koot HM, Verhulst FC (2007) Which better predicts conduct problems? The relationship of trajectories of conduct problems with ODD and ADHD symptoms form childhood to adolescence. J Child Psychol Psychiatry 48:601–608PubMedCrossRef
25.
Zurück zum Zitat Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP (2001) Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 40:188–196PubMedCrossRef Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP (2001) Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 40:188–196PubMedCrossRef
26.
Zurück zum Zitat Wigal SB, Wigal TL (2006) The laboratory school protocol: its origin, use, and new applications. J Atten Disord 10:92–111PubMedCrossRef Wigal SB, Wigal TL (2006) The laboratory school protocol: its origin, use, and new applications. J Atten Disord 10:92–111PubMedCrossRef
Metadaten
Titel
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder
A growth mixture modelling analysis
verfasst von
Edmund J. S. Sonuga-Barke
Pol Van Lier
James M. Swanson
David Coghill
Sharon Wigal
Mieke Vandenberghe
Simon Hatch
Publikationsdatum
01.06.2008
Verlag
D. Steinkopff-Verlag
Erschienen in
European Child & Adolescent Psychiatry / Ausgabe 4/2008
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-007-0667-3

Weitere Artikel der Ausgabe 4/2008

European Child & Adolescent Psychiatry 4/2008 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.